NCT03602508View on ClinicalTrials.gov

Treatment Persistence Among Patients With Overactive Bladder: A Retrospective Secondary Data Analysis in Asia Oceania

CompletedOBSERVATIONAL
Enrollment

5,589

Participants

Timeline

Start Date

July 20, 2018

Primary Completion Date

September 13, 2019

Study Completion Date

September 13, 2019

Conditions
Overactive Bladder (OAB)
Interventions
DRUG

mirabegron

oral

DRUG

solifenacin

oral

DRUG

darifenacin

oral

DRUG

imidafenacin

oral

DRUG

tolterodine

oral

DRUG

oxybutynin

oral

DRUG

trospium

oral

DRUG

fesoterodine

oral

DRUG

propiverine

oral

Trial Locations (2)

Unknown

Site AU10000, Sydney

Site KR82001, Seoul

All Listed Sponsors
lead

Astellas Pharma Singapore Pte. Ltd.

INDUSTRY

NCT03602508 - Treatment Persistence Among Patients With Overactive Bladder: A Retrospective Secondary Data Analysis in Asia Oceania | Biotech Hunter | Biotech Hunter